531 related articles for article (PubMed ID: 30592634)
1. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway.
Cheng J; Li Y; Liu S; Jiang Y; Ma J; Wan L; Li Q; Pang T
FASEB J; 2019 Apr; 33(4):4755-4764. PubMed ID: 30592634
[TBL] [Abstract][Full Text] [Related]
2. MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia.
Abdul-Aziz AM; Shafat MS; Mehta TK; Di Palma F; Lawes MJ; Rushworth SA; Bowles KM
Cancer Res; 2017 Jan; 77(2):303-311. PubMed ID: 27872094
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
4. Peptide hormone ELABELA promotes rat bone marrow-derived mesenchymal stem cell proliferation and migration by manipulating the cell cycle through the PI3K/AKT pathway under the hypoxia and ischemia microenvironment.
Chen X; Zhou C; Xu D; Liu X; Li S; Hou J; Zhang K; Zeng C; Zheng G; Wu H; Wu H; Wang W; Fu J; Wang T
Stem Cell Res Ther; 2022 Jan; 13(1):32. PubMed ID: 35090551
[TBL] [Abstract][Full Text] [Related]
5. The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling.
Forte D; Salvestrini V; Corradi G; Rossi L; Catani L; Lemoli RM; Cavo M; Curti A
Oncotarget; 2017 Jan; 8(2):2261-2274. PubMed ID: 27903985
[TBL] [Abstract][Full Text] [Related]
6. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
7. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T cells from patients with acute myeloid leukemia inhibit the proliferation of bone marrow-derived mesenchymal stem cells by secretion of miR-10a.
Yu Z; Li D; Ju XL
J Cancer Res Clin Oncol; 2016 Apr; 142(4):733-40. PubMed ID: 26590574
[TBL] [Abstract][Full Text] [Related]
9. CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-κB signaling pathway.
Shen T; Yang Z; Cheng X; Xiao Y; Yu K; Cai X; Xia C; Li Y
Oncol Rep; 2017 Apr; 37(4):2095-2100. PubMed ID: 28259918
[TBL] [Abstract][Full Text] [Related]
10. Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1.
Sun X; Yang S; Song W
Biomed Pharmacother; 2020 Apr; 124():109731. PubMed ID: 31954876
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway.
Zhang R; Tang P; Wang F; Xing Y; Jiang Z; Chen S; Meng X; Liu L; Cao W; Zhao H; Ma P; Chen Y; An C; Sun L
J Cell Biochem; 2019 Mar; 120(3):4423-4432. PubMed ID: 30367526
[TBL] [Abstract][Full Text] [Related]
12. CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway.
Jiang H; Wang X; Miao W; Wang B; Qiu Y
APMIS; 2017 Sep; 125(9):773-780. PubMed ID: 28736978
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
14.
Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
[No Abstract] [Full Text] [Related]
15. Hydrogen sulfide augments the proliferation and survival of human induced pluripotent stem cell-derived mesenchymal stromal cells through inhibition of BKCa.
Zhao Y; Wei H; Kong G; Shim W; Zhang G
Cytotherapy; 2013 Nov; 15(11):1395-405. PubMed ID: 23992829
[TBL] [Abstract][Full Text] [Related]
16. IL-8 Enhances Therapeutic Effects of BMSCs on Bone Regeneration via CXCR2-Mediated PI3k/Akt Signaling Pathway.
Yang A; Lu Y; Xing J; Li Z; Yin X; Dou C; Dong S; Luo F; Xie Z; Hou T; Xu J
Cell Physiol Biochem; 2018; 48(1):361-370. PubMed ID: 30016780
[TBL] [Abstract][Full Text] [Related]
17. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
18. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway.
Li JY; Ren KK; Zhang WJ; Xiao L; Wu HY; Liu QY; Ding T; Zhang XC; Nie WJ; Ke Y; Deng KY; Liu QW; Xin HB
Stem Cell Res Ther; 2019 Aug; 10(1):247. PubMed ID: 31399039
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.
Liu Y; Chen Y; Liu Y; Li M; Zhang Y; Shi L; Yang L; Li T; Li Y; Jiang Z; Liu Y; Wang C; Wang S
J Transl Med; 2022 Dec; 20(1):612. PubMed ID: 36550462
[TBL] [Abstract][Full Text] [Related]
20. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.
Jiang D; Wu X; Sun X; Tan W; Dai X; Xie Y; Du A; Zhao Q
J Nanobiotechnology; 2022 Jan; 20(1):29. PubMed ID: 35012554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
